Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Krystal Biotech Inc (KRYS)

Krystal Biotech Inc (KRYS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
KRYS Reports Upbeat Initial Data From Lung Cancer Study of KB707
KRYS Reports Upbeat Initial Data From Lung Cancer Study of KB707 Zacks Investment Research - Thu Dec 19, 11:22AM CST

Krystal Biotech KRYS announced encouraging initial clinical data from an early to mid-stage study of its investigational immunotherapy candidate, KB707, to treat patients with solid tumors of the lung.The...

KRYS : 164.83 (+2.49%)
CTMX : 1.0900 (-0.91%)
CSTL : 27.53 (+1.62%)
SPRO : 0.9551 (-4.30%)
Krystal Biotech Reports Preliminary Clinical Results for Inhaled KB707 in Advanced NSCLC Patients with 27% Objective Response Rate Quiver Quantitative, Inc. - Wed Dec 18, 5:24PM CST

Initial clinical results show inhaled KB707 achieved 27% ORR and 73% DCR in advanced NSCLC patients.Quiver AI SummaryKrystal Biotech, Inc. announced preliminary clinical data from its KYANITE-1 study,...

KRYS : 164.83 (+2.49%)
Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer GlobeNewswire - Wed Dec 18, 7:00AM CST

KRYS : 164.83 (+2.49%)
Insider Sale: President of $KRYS (KRYS) Sells 911 Shares Quiver Quantitative, Inc. - Sat Dec 14, 3:32AM CST

Suma Krishnan, the President of $KRYS ($KRYS), sold 911 shares of the company on 12-13-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 0.1% of their shares....

KRYS : 164.83 (+2.49%)
KRYS Stock Down on Initial Clinical Updates on KB407 & KB408
KRYS Stock Down on Initial Clinical Updates on KB407 & KB408 Zacks Investment Research - Fri Dec 13, 11:20AM CST

Krystal Biotech, Inc. KRYS announced initial clinical data updates on its two inhaled genetic medicine pipeline candidates, KB407 and KB408, which are being developed in early-stage studies for treating...

KRYS : 164.83 (+2.49%)
CTMX : 1.0900 (-0.91%)
CSTL : 27.53 (+1.62%)
SPRO : 0.9551 (-4.30%)
Krystal Biotech Announces Promising Clinical Data for KB408 Gene Therapy in Alpha-1 Antitrypsin Deficiency Patients and Progress on KB407 for Cystic Fibrosis Quiver Quantitative, Inc. - Thu Dec 12, 5:24PM CST

Krystal Biotech reports positive clinical data for KB408 and KB407, demonstrating safety and efficacy in AATD and cystic fibrosis patients.Quiver AI SummaryKrystal Biotech, Inc. has announced promising...

KRYS : 164.83 (+2.49%)
Krystal Biotech Announces Initial Clinical Update for Rare Respiratory Disease Programs KB408 and KB407 Including Early Clinical Evidence of Gene Delivery to the Lung of AATD Patients and Increase in Lung AAT to Therapeutic Levels GlobeNewswire - Thu Dec 12, 7:00AM CST

KRYS : 164.83 (+2.49%)
Krystal Biotech Provides Update on B-VEC EMA Review Timeline and Plans for German Market Launch Quiver Quantitative, Inc. - Tue Dec 10, 1:22AM CST

Krystal Biotech anticipates CHMP opinion in Q1 2025 and plans German launch of B-VEC for DEB in Q2 2025.Quiver AI SummaryKrystal Biotech, Inc. announced that the European Medicines Agency’s Committee...

KRYS : 164.83 (+2.49%)
Krystal Biotech Provides Update on EMA’s Ongoing Regulatory Review of B-VEC for Dystrophic Epidermolysis Bullosa GlobeNewswire - Mon Dec 9, 3:15PM CST

KRYS : 164.83 (+2.49%)
Krystal Biotech, Inc. CEO to Participate in Investor Conferences in December 2024 Quiver Quantitative, Inc. - Wed Nov 27, 4:16PM CST

Krystal Biotech's CEO to participate in investor conferences on December 3 and 4, 2024, with live webcasts available.Quiver AI SummaryKrystal Biotech, Inc. announced that CEO Krish S. Krishnan will participate...

KRYS : 164.83 (+2.49%)

Barchart Exclusives

Scalp a 47% Payout by the End of This Week with Micron (MU) Call Spreads Barchart - Sat Dec 21, 9:15AM CST
Yes, there are serious questions about MU stock following the underlying company’s disappointing earnings but a steady march is all options traders need. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot